• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国斯隆项目中微浸润性(浸润灶最大径≤1mm)导管原位癌(DCIS)患者的临床表现、诊治和转归

The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane Project.

机构信息

Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK.

NHS England and NHS Improvement, Birmingham, UK.

出版信息

Br J Cancer. 2022 Dec;127(12):2125-2132. doi: 10.1038/s41416-022-01983-4. Epub 2022 Oct 12.

DOI:10.1038/s41416-022-01983-4
PMID:36224403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9726983/
Abstract

BACKGROUND

The diagnosis, management and prognosis of microinvasive breast carcinoma remain controversial.

METHODS

We analysed the outcomes of patients with DCIS with and without microinvasion diagnosed between 2003 and 2012 within the Sloane project.

RESULTS

Microinvasion was recorded in 521 of 11,285 patients (4.6%), with considerable variation in reported incidence among screening units (0-25%). Microinvasion was associated with high-grade DCIS, larger DCIS size, comedo necrosis and solid, cribriform architecture (all P < 0.001). Microinvasion was more frequent in patients who underwent mastectomy compared with breast-conserving surgery (BCS) (6.9% vs 3.6%, P <  0.001), and in those undergoing axillary nodal surgery (60.4% vs 30.3%, P <  0.001) including the subset undergoing BCS (43.4% vs 8.5%, P < 0.001). Nodal metastasis rate was low and not statistically significant difference from the DCIS only group (P = 0.68). Following median follow-up of 110 months, 3% of patients had recurrent ipsilateral high-grade DCIS, and 4.2% developed invasive carcinoma. The subsequent ipsilateral invasion was of Grade 3 in 71.4% of patients with microinvasion vs 30.4% in DCIS without microinvasion (P = 0.02). Distant metastasis and breast cancer mortality were higher with microinvasion compared with DCIS only (1.2% vs 0.3%, P = 0.01 and 2.1% vs 0.8%; P = 0.005).

CONCLUSIONS

The higher breast cancer mortality with microinvasion indicates a more aggressive disease.

摘要

背景

微浸润性乳腺癌的诊断、治疗和预后仍存在争议。

方法

我们分析了 2003 年至 2012 年 Sloane 项目中诊断为 DCIS 伴或不伴微浸润的患者的结局。

结果

在 11285 例患者中,有 521 例(4.6%)记录有微浸润,各筛查单位的报告发病率差异较大(0-25%)。微浸润与高级别 DCIS、更大的 DCIS 大小、粉刺样坏死和实性、筛状结构有关(均 P<0.001)。与保乳手术(BCS)相比,接受乳房切除术的患者中微浸润更为常见(6.9%比 3.6%,P<0.001),接受腋窝淋巴结手术的患者也更为常见(60.4%比 30.3%,P<0.001),包括接受 BCS 的患者(43.4%比 8.5%,P<0.001)。淋巴结转移率较低,与仅 DCIS 组无统计学差异(P=0.68)。中位随访 110 个月后,3%的患者同侧出现高级别 DCIS 复发,4.2%发展为浸润性癌。有微浸润的患者同侧浸润性癌的分级为 3 级,无微浸润的患者为 30.4%(P=0.02)。与仅 DCIS 相比,有微浸润的患者远处转移和乳腺癌死亡率更高(1.2%比 0.3%,P=0.01;2.1%比 0.8%,P=0.005)。

结论

微浸润与更高的乳腺癌死亡率相关,表明疾病更具侵袭性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba5/9726983/35dcf8d65e01/41416_2022_1983_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba5/9726983/35dcf8d65e01/41416_2022_1983_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba5/9726983/35dcf8d65e01/41416_2022_1983_Fig1_HTML.jpg

相似文献

1
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane Project.英国斯隆项目中微浸润性(浸润灶最大径≤1mm)导管原位癌(DCIS)患者的临床表现、诊治和转归
Br J Cancer. 2022 Dec;127(12):2125-2132. doi: 10.1038/s41416-022-01983-4. Epub 2022 Oct 12.
2
Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.年龄对伴或不伴微浸润的导管原位癌行乳房切除术患者的局部区域和远处复发的影响。
Ann Surg Oncol. 2019 Dec;26(13):4264-4271. doi: 10.1245/s10434-019-07693-1. Epub 2019 Aug 22.
3
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.11337 例原发性导管原位癌(DCIS)患者的病理特征及后续事件:来自英国斯隆项目的结果。
Br J Cancer. 2021 Mar;124(5):1009-1017. doi: 10.1038/s41416-020-01152-5. Epub 2020 Nov 17.
4
Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project.乳腺单纯导管原位癌的放射学和病理学大小评估、标本处理以及对保乳手术成功率的影响:斯隆项目 2564 例回顾。
Br J Cancer. 2010 Jan 19;102(2):285-93. doi: 10.1038/sj.bjc.6605513. Epub 2010 Jan 5.
5
Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.多灶微浸润与保乳手术后导管原位癌女性浸润性局部复发风险增加相关。
Breast Cancer Res Treat. 2019 Nov;178(1):169-176. doi: 10.1007/s10549-019-05364-z. Epub 2019 Jul 19.
6
Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.英国国民保健署筛查性导管原位癌审计中对筛查性 DCIS 腋窝管理的变化:来自英国国民保健署乳腺筛查计划审计的证据。
Eur J Surg Oncol. 2015 Jan;41(1):86-93. doi: 10.1016/j.ejso.2014.09.003. Epub 2014 Oct 16.
7
Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis.乳腺导管原位癌微浸润的预后意义:一项荟萃分析。
Breast Cancer Res Treat. 2023 Jan;197(2):245-254. doi: 10.1007/s10549-022-06800-3. Epub 2022 Nov 24.
8
Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.保乳手术后原位导管癌与浸润性乳腺癌同侧乳腺肿瘤复发情况的比较。
World J Surg Oncol. 2016 Apr 27;14:126. doi: 10.1186/s12957-016-0885-6.
9
Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.原位导管癌且前哨淋巴结阳性的女性患者的结局:一项多机构审计
Ann Surg Oncol. 2007 Oct;14(10):2911-7. doi: 10.1245/s10434-007-9414-8. Epub 2007 Jun 28.
10
Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ.乳房切除术后针对筛查发现的导管原位癌进行的放射治疗。
Eur J Surg Oncol. 2015 Oct;41(10):1406-10. doi: 10.1016/j.ejso.2015.07.021. Epub 2015 Aug 18.

引用本文的文献

1
The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study.HER2阳性微浸润性乳腺癌的特征及这些患者进行全身辅助治疗的必要性:一项多中心真实世界研究
Ther Adv Med Oncol. 2025 Jun 16;17:17588359251345716. doi: 10.1177/17588359251345716. eCollection 2025.
2
Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis.HER2阳性T1micN0乳腺癌患者的治疗模式及临床结局:一项单中心分析
NPJ Breast Cancer. 2025 May 24;11(1):47. doi: 10.1038/s41523-025-00759-2.
3
Utility of Surgical Axillary Staging in Microinvasive Ductal Carcinoma In Situ: A National Cancer Database Analysis.
微浸润性导管原位癌手术腋窝分期的效用:一项国家癌症数据库分析
Ann Surg Oncol. 2025 Jun;32(6):4023-4033. doi: 10.1245/s10434-024-16727-2. Epub 2025 Apr 9.
4
Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.在乳房筛查期间发现非典型性病变,随后发生癌症:英格兰斯隆非典型性前瞻性队列的观察性分析。
BMJ. 2024 Feb 1;384:e077039. doi: 10.1136/bmj-2023-077039.
5
Prognostic Markers of Microinvasive Breast Carcinoma: A Systematic Review and Meta-Analysis.微浸润性乳腺癌的预后标志物:一项系统评价与Meta分析
Cancers (Basel). 2023 May 31;15(11):3007. doi: 10.3390/cancers15113007.
6
Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels.不同亚型和人表皮生长因子受体 2 表达水平的微浸润性乳腺癌的临床意义。
Breast Cancer Res Treat. 2023 Jul;200(1):47-61. doi: 10.1007/s10549-023-06955-7. Epub 2023 May 15.
7
Ductal Carcinoma In Situ (DCIS) and Microinvasive DCIS: Role of Surgery in Early Diagnosis of Breast Cancer.导管原位癌(DCIS)和微浸润性DCIS:手术在乳腺癌早期诊断中的作用
Healthcare (Basel). 2023 May 5;11(9):1324. doi: 10.3390/healthcare11091324.
8
Crossroads: the role of biomarkers in the management of lumps in the breast.十字路口:生物标志物在乳腺肿块管理中的作用。
Oncotarget. 2023 Apr 24;14:358-362. doi: 10.18632/oncotarget.28402.
9
Ductal carcinoma in situ with and without microinvasion: is there a clinically meaningful difference in outcome?伴有和不伴有微浸润的导管原位癌:其预后是否存在具有临床意义的差异?
Br J Cancer. 2023 Mar;128(5):713-714. doi: 10.1038/s41416-023-02152-x. Epub 2023 Jan 27.